44 Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-24,805
Closed -$618K 199
2025
Q4
$618K Buy
24,805
+254
+1% +$6.41K 0.21% 129
2025
Q3
$626K Buy
+24,551
New +$606K 0.21% 129
2025
Q1
Sell
-24,357
Closed -$646K 202
2024
Q4
$646K Sell
24,357
-1,791
-7% -$48.6K 0.25% 110
2024
Q3
$755K Buy
+26,148
New +$763K 0.27% 107
2023
Q2
$2.96M Buy
80,596
+1,332
+2% +$51.8K 1.01% 28
2023
Q1
$3.23M Buy
79,264
+3,591
+5% +$155K 1.09% 22
2022
Q4
$3.88M Buy
75,673
+8,596
+13% +$412K 1.34% 18
2022
Q3
$2.94M Buy
67,077
+6,090
+10% +$296K 1.21% 18
2022
Q2
$3.2M Buy
60,987
+5,594
+10% +$285K 1.24% 18
2022
Q1
$2.87M Buy
55,393
+6,110
+12% +$317K 1.03% 22
2021
Q4
$2.91M Buy
49,283
+1,344
+3% +$66.6K 1.01% 22
2021
Q3
$2.06M Buy
47,939
+4,116
+9% +$182K 0.79% 37
2021
Q2
$1.72M Buy
43,823
+13,180
+43% +$513K 0.66% 44
2021
Q1
$1.11M Buy
30,643
+10,798
+54% +$383K 0.46% 54
2020
Q4
$730K Buy
+19,845
New +$728K 0.33% 68

Other funds holding PFE

44 Wealth Management's PFE Position: Q1 2026 in Review

44 Wealth Management sold out of Pfizer (PFE) in Q1 2026, closing a stake of 24,805 shares — an estimated $618K sold.

44 Wealth Management first reported a position in PFE in Q4 2020 and held it in 15 quarters. The position peaked at $3.88M in Q4 2022. 2,952 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • 44 Wealth Management reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • 44 Wealth Management sold 24,805 Pfizer shares in Q1 2026, an estimated $618K.
  • 44 Wealth Management first reported a position in Pfizer in Q4 2020 and held it in 15 quarters.
  • 44 Wealth Management's Pfizer position peaked at $3.88M in Q4 2022.
  • 2,952 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on 44 Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.